½ÃÀ庸°í¼­
»óǰÄÚµå
1672958

Åëdz Ä¡·á ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº°, Áúȯ À¯Çüº°, À¯Åë ä³Îº°, Åõ¿© °æ·Îº°, Áö¿ªº°

Gout Disease Treatment Market, By Drug Class, By Disease Type, By Distribution Channel, By Route Of administration, By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è Åëdz Ä¡·á ½ÃÀåÀº 2025³â 30¾ï 4,000¸¸ ´Þ·¯, 2032³â¿¡´Â 53¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025-2032³â°£ ¿¬Æò±Õ 8.3% ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º¸°í ¹üÀ§ º¸°í¼­ »ó¼¼ ³»¿ë
±âÁØ ¿¬µµ 2024³â 2025³â ½ÃÀå ±Ô¸ð 30¾ï 4,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£(2025-2032³â) CAGR 8.30% 2032³â ±Ý¾× ¿¹Ãø 53¾ï 2,000¸¸ ´Þ·¯
±×¸². Åëdz Ä¡·á ½ÃÀå Á¡À¯À²(%), 2025³â Áö¿ªº° ½ÃÀå Á¡À¯À²
Gout Disease Treatment Market-IMG1

ÅëdzÀº ÀϹÝÀûÀÎ ¿°Áõ¼º °üÀý¿°ÀÇ ÀÏÁ¾À¸·Î ¿ä»ê °áÁ¤ÀÌ °üÀý(ÁÖ·Î ¾öÁö¹ß°¡¶ô)¿¡ ÃàÀûµÇ¾î ¹ß»ýÇÏ´Â ÁúȯÀÔ´Ï´Ù. ÅëdzÀº Çϳª ÀÌ»óÀÇ °üÀý¿¡ ÅëÁõ, ºÎÁ¾, ¾ÐÅëÀ» µ¿¹ÝÇÑ °©ÀÛ½º·´°í °Ý·ÄÇÑ ¹ßÀÛÀ» ÀÏÀ¸Åµ´Ï´Ù. ¼±Áø±¹ÀÇ ¾ËÄÚ¿Ã ¼Òºñ Áõ°¡, ºñ¸¸À² Áõ°¡, °í·ÉÈ­ µîÀÌ Åëdz À¯º´·ü Áõ°¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. Åëdz Ä¡·á ½ÃÀåÀº Åëdz Àç¹ßÀ» ¿¹¹æÇϱâ À§ÇÑ ¿ä»ê ¼öÄ¡ Á¶Àý¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ´õ ¸¹Àº Ä¡·á ¿É¼ÇÀÌ Á¦°øµÊ¿¡ µû¶ó ¼ºÀåÇÒ °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ

¼¼°è Åëdz Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀº Åëdz¿¡ Ãë¾àÇÑ ³ëÀÎ Àα¸ Áõ°¡, Åëdz À§Çè Áõ°¡·Î À̾îÁö´Â ºñ¸¸À² Áõ°¡, ¾ËÄڿðú Ç»¸°ÀÌ ¸¹ÀÌ ÇÔÀ¯µÈ ½ÄǰÀÇ ¼Òºñ Áõ°¡¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °üÀý ¼Õ»óÀ» ¿¹¹æÇϱâ À§ÇÑ ÅëdzÀÇ Á¶±â Áø´Ü ¹× Ä¡·á¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ½ÅÈï±¹ ½ÃÀåÀÇ 1Àδç ÀÇ·áºñ Áõ°¡, ½ÅÁ¦Ç° ½ÂÀÎ µîÀÌ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ±×·¯³ª ¾Ë·ÎÇ»¸®³îÀÇ Á¦³×¸¯ °æÀï, ¾à¹°ÀÇ ºÎÀÛ¿ë, ȯÀÚÀÇ º¹¾à ¼øÀÀµµ°¡ ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. »õ·Î¿î Ä¡·á ´ë»ó°ú ¾ÈÀü¼º ÇÁ·ÎÆÄÀÏÀ» °³¼±ÇÑ ÆÄÀÌÇÁ¶óÀÎ ÀǾàǰÀÇ °³¹ßÀº ½ÃÀå ÁøÃâ±â¾÷¿¡°Ô À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

  • ¼¼°èÀÇ Åëdz Ä¡·á ½ÃÀå¿¡ ´ëÇØ Á¶»ç ºÐ¼®ÇßÀ¸¸ç, 2024³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2025-2032³â) µ¿¾È ½ÃÀå ±Ô¸ð(10¾ï ´Þ·¯)¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» Á¶»çÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
  • ¶ÇÇÑ, ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¼öÀÍ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.
  • ¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ Áß¿äÇÑ °íÂûÀ» Á¦°øÇÕ´Ï´Ù.
  • º» º¸°í¼­´Â ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, À繫 ¼º°ú, Àü·« µîÀÇ ¸Å°³ º¯¼ö¸¦ ±â¹ÝÀ¸·Î ¼¼°è Åëdz Ä¡·á ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏÀ» Á¦°øÇÕ´Ï´Ù.
  • ÀÌ º¸°í¼­ÀÇ ÅëÂû·ÂÀ» ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ­, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
  • ¼¼°è Åëdz Ä¡·á ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷, À繫 ºÐ¼®°¡ µî ÀÌ »ê¾÷ÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
  • ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è Åëdz Ä¡·á ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ½±°Ô ³»¸± ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¸ñÀû°ú ÀüÁ¦Á¶°Ç

  • Á¶»ç ¸ñÀû
  • ÀüÁ¦Á¶°Ç
  • ¾à¾î

Á¦2Àå ½ÃÀå Àü¸Á

  • º¸°í¼­ ¼³¸í
    • ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
  • ÁÖ¿ä ¿ä¾à
  • Coherent Opportunity Map (COM)

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
  • ¿µÇ⠺м®
  • ½ÃÀå µ¿Çâ
  • ±ÔÁ¦ ½Ã³ª¸®¿À
  • Àμö¿Í Á¦ÈÞ ½Ã³ª¸®¿À
  • ÀÚ±ÝÁ¶´Þ°ú ÅõÀÚ
  • PEST ºÐ¼®
  • PorterÀÇ Five Forces ºÐ¼®

Á¦4Àå ¼¼°èÀÇ Åëdz Ä¡·á ½ÃÀå - Äڷγª¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ

  • ÀüüÀûÀÎ ¿µÇâ
  • Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºê
  • ½ÃÀå¿¡ ´ëÇÑ COVID-19ÀÇ ¿µÇâ

Á¦5Àå ¼¼°èÀÇ Åëdz Ä¡·á ½ÃÀå, ¾àÁ¦ Ŭ·¡½ºº°, 2020-2032³â(10¾ï ´Þ·¯)

  • ¼­·Ð
  • NSAIDs
  • ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å
  • ÄÝÈ÷Ä£
  • ¿ä»ê ÀúÇÏÁ¦
  • ±âŸ

Á¦6Àå ¼¼°èÀÇ Åëdz Ä¡·á ½ÃÀå, Áúȯ À¯Çüº°, 2020-2032³â(10¾ï ´Þ·¯)

  • ¼­·Ð
  • ±Þ¼º Åëdz
  • ¸¸¼º Åëdz

Á¦7Àå ¼¼°èÀÇ Åëdz Ä¡·á ½ÃÀå, À¯Åë ä³Îº°, 2020-2032³â(10¾ï ´Þ·¯)

  • ¼­·Ð
  • º´¿ø ¾à±¹
  • ¼Ò¸Å ¾à±¹
  • Àü¹® ¾à±¹

Á¦8Àå ¼¼°èÀÇ Åëdz Ä¡·á ½ÃÀå, Åõ¿© °æ·Îº°, 2020-2032³â(10¾ï ´Þ·¯)

  • ¼­·Ð
  • °æ±¸
  • ºñ°æ±¸

Á¦9Àå ¼¼°èÀÇ Åëdz Ä¡·á ½ÃÀå, Áö¿ªº°, 2020-2032³â(10¾ï ´Þ·¯)

  • ¼­·Ð
  • ºÏ¹Ì
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áßµ¿
  • ¾ÆÇÁ¸®Ä«

Á¦10Àå °æÀï ±¸µµ

  • ±â¾÷ °³¿ä
    • Takeda Pharmaceutical Company Ltd.
    • Novartis AG
    • Regeneron Pharmaceuticals Inc.
    • AstraZeneca plc
    • Horizon Therapeutics plc
    • Merck &Co. Inc.
    • Teijin Pharma Ltd.
    • GlaxoSmithKline, Plc.
    • Zydus Group
    • Menarini Group
    • JW Pharmaceutical
    • Simcere Pharmaceutical Group
    • Ionis Pharmaceuticals, Inc.
    • Selecta Biosciences
    • Mylan NV

Á¦11Àå ¾Ö³Î¸®½ºÆ® Ãßõ »çÇ×

  • À¶¼º°ú ¼èÅð
  • Coherent Opportunity Map

Á¦12Àå Âü°í ¹®Çå°ú Á¶»ç ¹æ¹ý

  • Âü°í ¹®Çå
  • Á¶»ç ¹æ¹ý
LSH 25.04.01

Global Gout Disease Treatment Market is estimated to be valued at USD 3.04 Bn in 2025 and is expected to reach USD 5.32 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.3% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 3.04 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 8.30% 2032 Value Projection: USD 5.32 Bn
Figure. Gout Disease Treatment Market Share (%), By Region 2025
Gout Disease Treatment Market - IMG1

Gout disease is a common form of inflammatory arthritis that occurs when uric acid crystals accumulate in the joints, typically in the big toe. It causes sudden and severe attacks of pain, swelling and tenderness in one or more joints. Rising consumption of alcohol, obesity rates and aging populations in developed nations have contributed to increase in gout prevalence globally. Global gout disease treatment market can witness growth as more treatment options become available and awareness increases about managing uric acid levels to prevent gout flares.

Market Dynamics:

Global gout disease treatment market growth is driven by growing geriatric population globally who are more prone to develop gout, rising obesity rates leading to higher risk of gout, increasing consumption of alcohol and purine-rich foods. Moreover, growing awareness about early diagnosis and treatment of gout to prevent joint damage, rising per capita healthcare expenditure in developing countries and new product approvals can drive the market growth. However, generic competition for allopurinol, side effects of drugs and patient non-adherence can hamper the market growth. The development of novel treatment targets and pipeline drugs with improved safety profiles can provide lucrative opportunities for market players.

Key Features of the Study:

  • This report provides in-depth analysis of the global gout disease treatment market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global gout disease treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Takeda Pharmaceutical, Novartis, AstraZeneca, Teijin Pharma, Mylan, and Horizon Therapeutics
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global gout disease treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global gout disease treatment market

Detailed Segmentation-

  • By Drug Class
    • NSAIDs
    • Corticosteroids
    • Colchicine
    • Urate-Lowering Agents
    • Others
  • By Disease Type
    • Acute Gout
    • Chronic Gout
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Specialty Pharmacies
  • By Route Of administration
    • Oral
    • Parentral
  • By Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Company Profiles:
    • Takeda Pharmaceutical Company Ltd.
    • Novartis AG
    • Regeneron Pharmaceuticals Inc.
    • AstraZeneca plc
    • Horizon Therapeutics plc
    • Merck & Co. Inc.
    • Teijin Pharma Ltd.
    • GlaxoSmithKline, Plc.
    • Zydus Group
    • Menarini Group
    • JW Pharmaceutical
    • Simcere Pharmaceutical Group
    • Ionis Pharmaceuticals, Inc.
    • Selecta Biosciences
    • Mylan N.V.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Drug Class
    • Market Snapshot, By Disease Type
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Route of Administration
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Regulatory Scenario
  • Acquisitions and Partnerships Scenario
  • Funding and Investments
  • PEST Analysis
  • Porter's Analysis

4. Global Gout Disease Treatment Market- Impact of Coronavirus (COVID-19) Pandemic

  • Overall Impact
  • Government Initiatives
  • COVID-19 Impact on the Market

5. Global Gout Disease Treatment Market, By Drug Class, 2020 - 2032, (USD Bn)

  • Overview
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2020 - 2032
    • Segment Trends
  • NSAIDs
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Corticosteroids
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Colchicine
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Urate-Lowering Agents
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Gout Disease Treatment Market, By Disease Type, 2020 - 2032, (USD Bn)

  • Overview
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2020 - 2032
    • Segment Trends
  • Acute Gout
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Chronic Gout
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Gout Disease Treatment Market, By Distribution Channel, 2020 - 2032, (USD Bn)

  • Overview
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2020 - 2032
    • Segment Trends
  • Hospital Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Retail Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Specialty Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Gout Disease Treatment Market, By Route Of administration, 2020 - 2032, (USD Bn)

  • Overview
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2020 - 2032
    • Segment Trends
  • Oral
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Parenteral
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Gout Disease Treatment Market, By Region, 2020 - 2032, (USD Bn)

  • Introduction
    • Market Share Analysis, By Region, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, For Region, 2020-2032
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USDBn)
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
      • North Africa
      • Central Africa
      • South Africa

10. Competitive Landscape

  • Company Profiles
    • Takeda Pharmaceutical Company Ltd.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Novartis AG
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Regeneron Pharmaceuticals Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • AstraZeneca plc
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Horizon Therapeutics plc
    • Merck & Co. Inc.
    • Teijin Pharma Ltd.
    • GlaxoSmithKline, Plc.
    • Zydus Group
    • Menarini Group
    • JW Pharmaceutical
    • Simcere Pharmaceutical Group
    • Ionis Pharmaceuticals, Inc.
    • Selecta Biosciences
    • Mylan N.V.

11. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

12. References and Research Methodology

  • References
  • Research Methodology
  • About Us and Sales Contact
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦